The development of mature blood cells from hematopoietic stem cells is precisely regulated. Expression of cytokine receptors, survival programs, and other key proteins provide the means for individual cells to survive, proliferate, differentiate and/or function. Control of transcription of genes is responsible for these cellular programs is one level of regulation. PU.1, and ets family member, is expressed in primitive hematopoietic cells and is up-regulated during myeloid and B cell development. Without PU.1 there is no development of B cells, mature dendritic cells and monocytes/macrophages and no terminal differentiation of neutrophils. Therefore, how do transcription factors, such as PU.1, assemble with specific transcriptional partners to promote commitment and maturation of many different lineages? Furthermore, must PU.1 be continuously expressed to maintain neutrophil dendritic cell and monocyte/macrophage differentiation? To define the mechanisms by which PU.1 promotes myeloid and lymphoid lineage commitment and maturation we propose to address in our Specific Aims: 1. Which PU.1 subdomains within the transactivation and PEST domains promote myeloid and lymphoid development in vivo? In this Specific Aim we will explore the molecular requirements for various subdomains by restoration of freshly isolated PU.1 null hematopoietic cells with PU.1 mutants and then evaluate gain of specific gene expression and cell function. Selected PU.1 mutants will then be assessed for their regulation of development in vivo. 2. What are the roles of PU.1 in the development of myeloid and lymphoid dendritic cells? We will elucidate the cellular and molecular mechanisms responsible for the in vivo less of both myeloid and lymphoid dendritic cells. We will also evaluate the roles of PU.1 subdomains in dendritic cell development. 3. Must PU.1 expression is maintained during and after neutrophil and monocyte development? We will examine the requirement for PU.1 after development ensures and in mature cells by using conditional PU.1 expressing mice that are homozygous for the PU.1 null allele. Completion of these proposed studies will help to elucidate molecular and cellular mechanisms governing hematopoietic development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK054938-04
Application #
6523762
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Badman, David G
Project Start
1999-08-01
Project End
2004-07-31
Budget Start
2002-08-01
Budget End
2004-07-31
Support Year
4
Fiscal Year
2002
Total Cost
$297,226
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Batliner, Jasmin; Mancarelli, Maria Michela; Jenal, Mathias et al. (2011) CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation. Mol Immunol 48:714-9
Jenal, M; Batliner, J; Reddy, V A et al. (2010) The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1. Leukemia 24:1073-6
Blancafort, Pilar; Tschan, Mario P; Bergquist, Sharon et al. (2008) Modulation of drug resistance by artificial transcription factors. Mol Cancer Ther 7:688-97
Britschgi, Christian; Jenal, Mathias; Rizzi, Mattia et al. (2008) HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation. Br J Haematol 141:179-87
Rizzi, Mattia; Tschan, Mario P; Britschgi, Christian et al. (2007) The death-associated protein kinase 2 is up-regulated during normal myeloid differentiation and enhances neutrophil maturation in myeloid leukemic cells. J Leukoc Biol 81:1599-608
Gombart, Adrian F; Kwok, Scott H; Anderson, Karen L et al. (2003) Regulation of neutrophil and eosinophil secondary granule gene expression by transcription factors C/EBP epsilon and PU.1. Blood 101:3265-73
Manchester, Marianne; Smith, Kent A; Eto, Danelle S et al. (2002) Targeting and hematopoietic suppression of human CD34+ cells by measles virus. J Virol 76:6636-42